Current treatments

Determining treatment intensity in elderly patients with multiple myeloma. Salvini M et al. Expert Rev Anticancer Ther. 2018 Sep. doi: 10.1080/14737140.2018.1496823. [Epub 2018 Jul 13] Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Chari A et al. Future Oncol. 2018 Sep. doi: 10.2217/fon-2017-0727. [Epub 2018 May 30] Autologous stem cell transplantation in first…

Details

General

The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets. Abramson HN. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.015. [Epub 2018 Jun 18] A new conceptual framework for the therapy by optimized multidimensional pulses of therapeutic activity. The case of multiple myeloma model. Horvath D and Brutovsky B. J Theor Biol. 2018 Oct 7. doi: 10.1016/j.jtbi.2018.06.015. [Epub 2018 Jun…

Details

Biology and genetics

Bortezomib Targets Sp Transcription Factors in Cancer Cells. Karki Ket al. Mol Pharmacol. 2018 Oct. doi: 10.1124/mol.118.112797. [Epub 2018 Aug 16] IRF4 in multiple myeloma-Biology, disease and therapeutic target. Agnarelli A et al. Leuk Res. 2018 Sep. doi: 10.1016/j.leukres.2018.07.025. [Epub 2018 Aug 3] PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism. Zhang H et al. Mol Oncol. 2018 Sep.…

Details

Emerging treatments

Ixazomib: a novel drug for multiple myeloma. Zanwar S et al. Expert Rev Hematol. 2018 Sep 1. doi: 10.1080/17474086.2018.1518129. [Epub ahead of print] A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. San-Miguel JF et al. Haematologica. 2018 Sep. doi: 10.3324/haematol.2017.185991. [Epub 2018 Jun 28] Phase I study…

Details

Complications of myeloma and its treatments

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print] Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. Lee AC et al. J…

Details

Myeloma UK is helping to Make Blood Cancer Visible this September

Myeloma UK is helping to Make Blood Cancer Visible in September. The campaign, in partnership with Janssen Oncology and eight patient organisations, marks Blood Cancer Awareness Month. It will feature a public art installation, which will help visitors to understand the experiences of people affected by blood cancer.   The installation is made up of…

Details